Navigation Links
Experiment station researchers to explore genome of disease-fighting fungus

A team of Texas Agricultural Experiment Station scientists will soon begin genome sequencing a disease-fighting fungus used to protect crops, which has implications for both agriculture and the pharmaceutical industry.

The fungus, Trichoderma virens, is used to protect field crops from various plant diseases. Researchers say the genome sequencing work may uncover chemical compounds and beneficial genes useful in producing new human and animal antibiotics.

The sequencing project is a collaborative effort with the Department of Energy Joint Genome Institute. Experiment Station plant pathologists are Drs. Charles M. Kenerley, Daniel J. Ebbole, Heather H. Wilkinson and Michael Thon. Also working on the project is Dr. Alfredo Herrera-Estrella, from the Center for Research and Advanced Studies in Mexico.

"There's both pharmaceutical and agricultural implications," said Kenerley, who is the lead researcher on the project. "We're going to get a view of all of the genes that might be responsible for producing antibiotics and potentially discover novel antibiotics used in therapy for humans or animals.

"We know some of the genes responsible for known antibiotics, however, there are additional genes in Trichoderma responsible for producing uncharacterized compounds that might be novel antibiotics."

By sequencing the fungus, researchers say they will be able to develop new versions of the fungus to protect field crops from diseases. This would decrease the amount of pesticide and other chemicals applied throughout a growing season.

"You also might be able to more effectively employ sustainable practices such as low till agriculture," said Wilkinson, who is researching the ecological aspects of the fungus. "You've got Trichoderma present to combat the pathogens that remain in the soil when you incorporate low till. In theory, it would be cost-effective for many producers.

"By placing the disease-fighting fungus directly onto
'"/>

Source:Texas A&M University - Agricultural Communications


Page: 1 2

Related biology news :

1. Experiments provide proof of how traveling in groups protects insects
2. Experiments provide proof of how traveling in groups protects insects
3. NIAID Initiates Trial of Experimental Avian Flu Vaccine
4. Duke Experiments Boost Radiations Cancer-Killing Effects
5. Experimental shingles vaccine proves effective in nationwide study
6. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
7. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
8. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
9. Experimental RNA-based drug kills prostate cancer cells effectively and safely
10. Experimental vaccine protects lab animals against several strains of H5N1
11. Experimental vaccine protects mice against deadly 1918 flu virus
Post Your Comments:
(Date:7/31/2014)... France, and the U.S. has discovered and described ... member of the tribe Omaliini that has ever ... were made possible through the use of the ... the detailed study of otherwise invisible specimens in ... the journal Annals of the Entomological Society ...
(Date:7/31/2014)... release is available in German . ... take up gases similar to a sponge that soaks ... for storing hydrogen or greenhouse gases. However, loading of ... Institute of Technology (KIT) now report in Nature ... of the MOF surface. This can be prevented by ...
(Date:7/31/2014)... vaccine protected 100 percent of animal models against the ... which causes an intestinal disease that kills approximately 30,000 ... in Infection and Immunity . , In ... primates against the purified toxins produced by C. ... infection, a laboratory model that mimics the human disease, ...
Breaking Biology News(10 mins):Free pores for molecule transport 2C. difficile vaccine proves safe, 100 percent effective in animal models 2
... Studying thousands of patients, Japanese researchers have found a ... three cancers esophageal, head and neck, and lung. ... of developing these diseases. In the May issue ... the American Association for Cancer Research, scientists from Aichi ...
... A Swiss marine biologist and an Australian quantum physicist have ... Reef, Australia, can see a world invisible to all other ... have shown that mantis shrimp not only have the ability ... but have optimal polarisation vision a first for any ...
... in the February 2008 issue of HortScience offers new ... athletic fields ready for fall sports more quickly. Results ... pare down the usual 9- to 12-month waiting period ... autumn football traffic. Dr. John Stier, Associate Professor ...
Cached Biology News:Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer 2Shrimps see beyond the rainbow 2Shrimps see beyond the rainbow 3Establishing faster-growing, durable football fields 2
(Date:7/31/2014)... Francisco, California (PRWEB) July 31, 2014 ... systems that inform therapeutic decision-making in oncology, today announced ... August 14, 2014 to discuss the Company's financial results ... provide an update about the business in the current ... audio call beginning on Thursday, August 14, 2014, at ...
(Date:7/31/2014)... 31, 2014 Rancho BioSciences , ... of Omicsoft’s Array Suite with tranSMART . ... able to send data in tranSMART to Array Suite ... versions of tranSMART including the new 1.2 release. ... and storage for the analysis of high dimensional quantification ...
(Date:7/31/2014)... MA (PRWEB) July 31, 2014 ... (UC) and collaboration company, is proud to announce ... (LMS). LMS complements Adobe Connect’s elearning tools to ... LMS delivers content with training tools for desktop ... eLearning with LMS is the perfect online training ...
(Date:7/30/2014)... TARRYTOWN, N.Y. and PARIS ... REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today ... Food and Drug Administration (FDA) rare pediatric disease priority ... (BLA) submission for alirocumab.  The priority review voucher entitles ... which provides for an expedited 6-month review from the ...
Breaking Biology Technology:CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... , SOUTH PLAINFIELD, N.J., Sept. 2 PTC ... its option to collaborate on advancing drug discovery efforts on ... (Gene Expression Modulation by Small-molecules) technology. , , ... , , In September 2007, Celgene made ...
... , SAN DIEGO, Sept. 2 Results from ... developmental product candidates will be presented at the ... held at The Moscone Center in San Francisco on September 12-15, 2009. ... , , , Fidaxomicin ...
... , SOUTH SAN FRANCISCO, Calif., Sept. ... the first commercial sales of a new 20 microgram per ... York Heart Association Class III and IV pulmonary arterial hypertension ... Ventavis in half the volume, which is expected to reduce ...
Cached Biology Technology:PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 2Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States 3
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
... Linkage: This CLS number ... created to easily match Cornings ... availability yet, please order under ... or contact customer service for ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... cultured in DMEM and harvested at the log ... the antigens in their native forms, cells were ... on a 12-well (5 mm) adhesive coated slide, ... cellular attachment and to minimize background staining. ...
Biology Products: